Citadel Advisors’s Alexza Pharmaceuticals Inc ALXA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q2
– Sell
-21,244
Closed -$10K – 8053
2016
Q1
$10K Buy
+21,244
New +$9.29K ﹤0.01% 6773
2015
Q2
– Sell
-21,327
Closed -$44K – 9555
2015
Q1
$44K Sell
21,327
-4,288
-17% -$8.8K ﹤0.01% 7635
2014
Q4
$38K Sell
25,615
-409
-2% -$730 ﹤0.01% 7579
2014
Q3
$61K Buy
26,024
+14,843
+133% +$56.7K ﹤0.01% 6953
2014
Q2
$51K Sell
11,181
-2,010
-15% -$8.68K ﹤0.01% 6900
2014
Q1
$58K Buy
13,191
+9,939
+306% +$51K ﹤0.01% 6819
2013
Q4
$15K Buy
+3,252
New +$16K ﹤0.01% 6609
2013
Q3
– Sell
-1,691
Closed -$7.96K – 7011
2013
Q2
$7K Hold
1,691
– – ﹤0.01% 6312

Citadel Advisors's ALXA Position: Q2 2016 in Review

Citadel Advisors sold out of Alexza Pharmaceuticals Inc (ALXA) in Q2 2016, closing a stake of 21,244 shares — an estimated $10K sold.

Citadel Advisors first reported a position in ALXA in Q2 2013 and held it in 8 quarters. The position peaked at $61K in Q3 2014. 0 funds tracked by Wall St. Rank hold ALXA as of Q2 2016.

  • Citadel Advisors reported no remaining Alexza Pharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
  • Citadel Advisors sold 21,244 Alexza Pharmaceuticals Inc shares in Q2 2016, an estimated $10K.
  • Citadel Advisors first reported a position in Alexza Pharmaceuticals Inc in Q2 2013 and held it in 8 quarters.
  • Citadel Advisors's Alexza Pharmaceuticals Inc position peaked at $61K in Q3 2014.
  • 0 funds tracked by Wall St. Rank held Alexza Pharmaceuticals Inc as of Q2 2016.

Based on Citadel Advisors's 13F filing for Q2 2016, filed 12 Aug 2016.